



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In application of:

Bertram Weiss et al.

**BOX SEQUENCE**

Serial No.: 09/867,753

Examiner:

Filed: May 31, 2001

Group Art Unit:

For: HUMAN PEM AS A TARGET FOR BIRTH CONTROL AND TREATMENT OF  
ALZHEIMER'S DISEASE

**RESPONSE TO NOTICE TO COMPLY  
WITH SEQUENCE DISCLOSURE REQUIREMENTS**

Assistant Commissioner for Patents  
Washington, D.C. 20231

Sir:

This paper is responsive to the Communication from the Examiner dated June 25, 2001. SEQ ID NOS. 1-3 are assigned according to the application as filed, while SEQ ID NOS. 4-6 are included in the attached page 13 to be substituted in the specification. A copy of the sequence listing in computer readable form, along with a statement, is also being provided.

Respectfully submitted,

\_\_\_\_\_  
Anthony J. Zelano  
Registration No. 27,969  
Attorney for Applicant(s)

MILLEN, WHITE, ZELANO,  
& BRANIGAN, P.C.  
Arlington Courthouse Plaza I, Suite 1400  
2200 Clarendon Boulevard  
Arlington, Virginia 22201  
Telephone: (703) 243-6333  
Facsimile: (703) 243-6410

Attorney Docket No.: SCH-1810  
**Filed: August 24, 2001**

### Example

The expression of the human PEM in various brain tissues was analyzed by semi-quantitative PCR. To this end, the following primers were used:

Sense 5'-ATGGCGCGTTCGCTCGTCCACGAC-3', (SEQ ID NO 4)

Antisense 5'-TAGTCCACGACGATGTAGACACAG-3'. (SEQ ID NO 5)


In the control, specific primers for beta-actin were used:

Sense primer 5'-CTAGAAGCATTTCGCGGTGGACGATGGAGGG-3', (SEQ ID NO 6)

Antisense primer 5'-CTAGAAGCATTTCGCGGTGGACGATGGAGGG-3'. (SEQ ID NO 6)

The cDNA was acquired by Invitrogen (Carlsbad, CA, USA).

The PCR analysis was performed with the Advantage-2 PCR kit (Clontech). The reaction conditions were as follows: initially 5 minutes at 95°C; then 30 cycles with 95°C for 30 seconds, 62°C for 30 seconds and 72°C for 1 minute; finally 72°C for 7 minutes. The results show an elevated expression of human PEM in the frontal and temporal lobes in Alzheimer patients in comparison to healthy tissue.



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Atty. Docket No: SCH-1810

I, the patent application of

WEISS, BERTRAM et al.

Serial No. 09/867,753

Filed: May 31, 2001

For: HUMAN PEM AS A TARGET FOR BIRTH CONTROL AND TREATMENT OF ALZHEIMER'S  
DISEASE

STATEMENT TO SUPPORT FILING AND SUBMISSION IN  
ACCORDANCE WITH 37 C.F.R. §§ 1.821-1.825

Assistant Commissioner for Patents  
Washington, D.C. 20231  
**Box SEQUENCE**

Sir:

In connection with a Sequence Listing submitted concurrently  
herewith, the undersigned hereby states that:

1. the submission, filed herewith in accordance with 37  
C.F.R. § 1.821(g), does not include new matter;

2. the content of the attached paper copy and the  
attached computer readable copy of the Sequence Listing, submitted in  
accordance with 37 C.F.R. § 1.821(c) and (e), respectively, are the same;  
and

3. all statements made herein of their own knowledge are  
true and that all statements made on information and belief are believed to  
be true; and further, that these statements were made with the knowledge  
that willful false statements and the like so made are punishable by fine  
or imprisonment, or both, under Section 1001 of Title 18 of the United

09867753-032401